FLT3 and acute myeloid leukemia: Ilorasertib (ABT-348; Figure 5), an Aurora/VEGF inhibitor also potent against FLT3 [76], demonstrated clinical response in 3 out of 38 AML patients in a Phase 1 dose-escalation clinical study [77].